BMO raises Vital Farms stock price target on strategic actions

Vital Farms (VITL) delivered Q2 revenue of $166M (vs $160M Street, but down 10.1% YoY), while adjusted EBITDA was a loss of $27M vs -$21M, confirming earnings pressure. The company maintained fiscal 2026 guidance of $775M–$800M revenue and $0–$10M adjusted EBITDA, and secured $185M of new revolving credit facilities while terminating its share repurchase authorization. BMO raised its VITL price target to $15 (Outperform) on expectations of a recovery toward high-single-digit adjusted EBITDA margin by fiscal 2027, but the results still point to an earnings trough and potential near-term volatility.

Analysis

Vital Farms is transitioning from a growth-at-any-cost story to a balance-sheet-first turnaround, and that usually means the equity rerates only after the market sees proof that volume can recover without permanent margin damage. The key issue is not the current EBITDA miss; it is that price cuts in a commoditized protein category tend to transmit quickly to revenue but slowly to gross margin, especially when supply is still excess. That creates a longer trough than sell-side models typically allow, because retailers take the benefit immediately while suppliers absorb the reset first.

The new liquidity backstop lowers near-term distress risk, but the termination of repurchases removes an important technical support and signals that management would rather preserve cash than defend per-share value. In practice, that shifts the stock from a capital-return story to a pure operating execution trade, which generally deserves a lower multiple until trailing margins stabilize. Downstream, supermarkets and mass retailers are the quiet beneficiaries if egg prices normalize; premium-branded producers are the ones forced to cut first, and that often pulls the whole category into a margin war.

Contrarian view: the market may already be discounting a trough, but the consensus seems too willing to extrapolate a 2027 margin recovery from a few quarters of corrective action. The thesis is falsified if gross margin expands materially before revenue re-accelerates, or if fiscal 2026 EBITDA falls meaningfully below the current range. Absent that, the better timing is to wait for any relief rally and fade it rather than chase a bottoming call today.

Key Decisions for Investors

• Short VITL into any 1-2 week post-earnings bounce; use a 3-6 month put spread to define risk. Base case is that the stock stays range-bound until the market sees two clean quarters of margin recovery; thesis breaks if fiscal 2026 EBITDA moves decisively above guidance midpoints.
• If looking for a cleaner relative-value expression, pair short VITL vs long a defensive food retailer basket (TGT as the most liquid single-name proxy) over the next 1-3 months. The trade works if lower protein input costs flow through to retailer gross margin faster than VITL can recapture pricing.
• Set a watch alert for VITL gross margin and volume mix in the next two earnings prints. If management cannot show at least 200-300 bps of sequential margin improvement by the next update, the 2027 high-single-digit EBITDA target likely gets pushed out, which would justify another leg lower.
• For patient capital, wait for a capitulation entry only after guidance is cut or inventory days normalize. The upside case is real, but the current setup still has more operating downside than equity upside.